Overview

Memantine for Epileptic Encephalopathy

Status:
Recruiting

Trial end date:
2022-05-31

Target enrollment:

Participant gender:

Summary

This study will evaluate the potential benefit of memantine hydrochloride as treatment for children with epileptic encephalopathy using a double-blind placebo-controlled cross-over design.

Phase:

Phase 4

Details

Lead Sponsor:

Kenneth Myers, MD

Treatments:

Memantine